RUA Life Sciences has reported FY25 results, covering the 18-month period to September 2025, given the recent change of year-end, and include the first-time contribution from Abiss, acquired in September 2024. Reported revenues were £6.7m, slightly ahead of the expectations provided with the trading update (November 2025) and RUA delivered an adjusted EBITDA profit of c£0.6m, including a gain on acquisition of c£0.9m. Cash at the close of September 2025 was £3.3m, again slightly ahead of the tra ....
